次世代薬物複合体市場規模、シェア、動向、2035年までの世界予測

次世代薬物複合体の世界市場は、2026年の157億5,000万米ドルから2035年には425億5,000万米ドルに成長し、2026年から2035年の予測期間中の年平均成長率（CAGR）は11.7%に達するとMarketsandMarketsでは予測しています。

次世代薬物複合体の世界市場は、標的療法の採用の増加、リンカー、ペイロード、標的リガンド技術の継続的な革新、および腫瘍学に特化した医薬品開発への投資の増加に支えられ、予測期間中に力強い成長が見込まれています。公表されている業界情報源からの市場予測では、これらの治療法の強力な臨床的および商業的勢いを反映して、2034年まで力強い二桁成長が示されています。しかし、安全性への懸念、製造の複雑さ、および高額な治療費は、より広範な市場拡大を抑制する主要因として残ると予想されます。

調査範囲

本調査レポートは、次世代薬物複合体市場を、製品別（Enhertu [ファム-トラスツズマブ デルクステカン-nxki]、Pluvicto [ルテチウムLu 177ビピボチド テトラキセタン]、AMVUTTRA [ヴトリシラン]、TRODELVY [サシツズマブ ゴビテカン-hziy]、サシツズマブ ティルモテカン、パトリツマブ デルクステカン [HER3-DXd]、225Ac-PSMA-617、その他の市販製品およびパイプライン製品）、タイプ別（抗体-低分子薬物複合体、リガンド-オリゴヌクレオチド複合体、低分子-放射性核種複合体、ペプチド-放射性核種複合体、その他の複合体タイプ）、標的リガンド別（抗体、アミノ糖、低分子、ペプチド）、ペイロードタイプ別（低分子、オリゴヌクレオチド、放射性核種）に分類しています。適応症別（乳がん、前立腺がん、多発性神経障害を伴うhATTR症候群、原発性高脂血症、その他の適応症）および地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分析を行っています。

本レポートでは、次世代薬物複合体（NDCs）市場の成長に影響を与える主要な要因（推進要因、課題、機会、制約など）に関する詳細な情報を提供しています。主要企業の詳細な分析を行い、事業概要、製品ポートフォリオ、製品承認・発売、提携、パートナーシップ、事業拡大、契約、次世代薬物複合体市場における最近の動向といった主要戦略に関する洞察を提供しています。また、次世代薬物複合体市場のエコシステムにおける主要企業および新興企業の競合分析も行っています。

本レポートを購入する主なメリット

本レポートは、市場リーダーや新規参入企業に対し、次世代薬物複合体（NDCs）市場全体およびそのサブセグメントの収益に関する最も正確な概算値を提供することで、市場戦略の策定を支援します。このレポートは、関係者が競争環境をより深く理解し、自社の事業をより適切に位置づけ、適切な市場参入戦略を策定するための洞察を得るのに役立ちます。また、市場の動向を把握し、主要な市場推進要因、阻害要因、機会、課題に関する情報を提供します。

本レポートは、以下のポイントに関する洞察を提供します。

• 次世代薬物複合体市場の成長に影響を与える主要な推進要因（抗体薬物複合体の臨床的成功と規制当局の承認の増加、リンカー化学とペイロード開発における技術進歩）、阻害要因（複雑な生物製剤に関連する高い開発および製造コスト）、機会（薬物複合体の非腫瘍治療領域への拡大）、および課題（複雑な臨床試験設計と患者選択要件）の分析
• 製品開発／イノベーション：次世代薬物複合体市場で新たに発売された製品に関する詳細な洞察
• 市場開発：有望な市場に関する包括的な情報 – 本レポートは、さまざまな地域における次世代薬物複合体市場を分析しています
• 市場の多様化：次世代薬物複合体市場における新製品、未開拓地域、最近の動向、および投資に関する包括的な情報
• 競合評価：主要企業の市場シェア、成長戦略、および製品提供に関する詳細な評価（Alnylam Pharmaceuticals（米国）、Gilead Sciencesなど）次世代薬物複合体市場には、Inc.（米国）、ノバルティスAG（スイス）、アストラゼネカ（英国）、第一三共株式会社（日本）、アイオニス・ファーマシューティカルズ社（米国）などがある。

Report Description

The global next generation drug conjugates market is estimated to reach USD 42.55 billion by 2035 from USD 15.75 billion in 2026, at a CAGR of 11.7% during the forecast period of 2026 to 2035. The global next generation drug conjugates market is projected to witness strong growth over the forecast period, supported by rising adoption of targeted therapies, continued innovation in linker, payload, and targeting ligand technologies, and increasing investment in oncology-focused drug development. Market estimates from published industry sources indicate robust double-digit growth through 2034, reflecting strong clinical and commercial momentum for these therapies. However, safety concerns, manufacturing complexity, and high treatment costs are expected to remain key factors restraining broader market expansion.

“The Enhertu product segment accounted for the largest share by product in the next generation drug conjugates market in 2025.”

Based on product, the next generation drug conjugates market is broadly segmented into Enhertu (fam-trastuzumab deruxtecan-nxki), Pluvicto (lutetium Lu 177 vipivotide tetraxetan), Amvuttra (vutrisiran), Trodelvy (sacituzumab govitecan-hziy), Sacituzumab tirumotecan, Patritumab Deruxtecan (HER3-DXd), 225Ac-PSMA-617, other commercialized products and other pipeline products. The ENHERTU segment held the largest market share in 2025. This leadership can be attributed to several factors, including its strong efficacy across multiple HER2-expressing tumor types, rapid label expansion beyond metastatic breast cancer into broader solid tumor settings, and its differentiated DXd payload and bystander effect, which have strengthened physician confidence and treatment adoption. In addition, Enhertu has benefited from growing global commercial penetration, increasing use in earlier lines of therapy, and strong backing from AstraZeneca and Daiichi Sankyo’s extensive development and commercialization capabilities.

“The antibody-small molecule drug conjugate segment accounted for the largest share by type segment in the next generation drug conjugates market in 2025.”

Based on end users, the global next generation drug conjugates market is segmented into antibody-small molecule drug conjugates, ligand-oligonucleotide conjugates, small molecule-radionuclide conjugates, peptide-radionuclide conjugates, and other conjugate types. In 2025, the antibody-small molecule segment accounted for the largest share of the market. This is primarily because antibody-drug conjugates are the most clinically established and commercially advanced class within targeted conjugates, with continued technological progress improving outcomes across multiple tumor types.

“North America is growing at the highest CAGR in the next generation drug conjugates market from 2026 to 2035.”

The next generation drug conjugates market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. During the forecast period, the North American region is estimated to grow at the highest CAGR. This growth is expected to be supported by the region’s strong concentration of biopharmaceutical innovation, early adoption of advanced targeted therapies and the presence of key market participants, such as Novartis, Pfizer and Alnylam, actively developing and commercializing next generation drug conjugates.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70% and Demand Side – 30%
• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: CXOs and Directors – 30%, Managers – 45%, and Others – 25%
• By Region: North America – 40%, Europe – 25%, Asia Pacific – 20%, Latin America – 10%, and the Middle East – 5%

List of Companies Profiled in the Report

• Alnylam Pharmaceuticals
• Gilead Sciences, Inc.
• Novartis AG
• AstraZeneca
• Daiichi Sankyo Company, Limited
• Ionis Pharmaceuticals, Inc.
• Rakuten Group
• Novo Nordisk
• ADC Therapeutics SA
• Sanofi
• Arrowhead Pharmaceuticals
• Abbvie
• Regeneron Pharmaceuticals, Inc.
• Bicycle therapeutics
• Avidity Biosciences
• Silence Therapeutics
• MediLink Therapeutics
• SystImmune, Inc.
• Actinium Pharmaceuticals
• Alphamab Oncology
• Fusion Pharma
• Orano group
• PepGen Inc
• Tubulis GmbH
• Clarity Pharmaceuticals

Research Coverage

This research report categorizes the next generation drug conjugates market by product (Enhertu [fam-trastuzumab deruxtecan-nxki], Pluvicto [lutetium Lu 177 vipivotide tetraxetan], AMVUTTRA [vutrisiran], TRODELVY [sacituzumab govitecan-hziy], Sacituzumab tirumotecan, Patritumab Deruxtecan [HER3-DXd], 225Ac-PSMA-617, other commercialized products and other pipeline products); by type: antibody-small molecule drug conjugate, ligand-oligonucleotide conjugate, small molecule-radionuclide conjugate, peptide-radionuclide conjugate, and other conjugate types; by targeting ligand: antibody, amino sugar, small molecule and peptide; by payload type: small molecule, oligonucleotide, and radionuclide; by indications: breast cancer, prostate cancer, hATTR with polyneuropathy, primary hyperlipidemia and other indications; and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints, influencing the growth of the next generation drug conjugates market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product portfolio, key strategies such as product approvals and launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the next generation drug conjugates market. Competitive analysis of top players and upcoming startups in the next generation drug conjugates market ecosystem is covered in this report.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall next generation drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing clinical success and regulatory approvals of antibody-drug conjugates, technological advancements in linker chemistry and payload development), restraints (high development and manufacturing costs associated with complex biologics), opportunities (expansion of drug conjugates into non-oncology therapeutic areas) and challenges (complex clinical trial design and patient selection requirements) are influencing the growth of next generation drug conjugates market
• Product Development/Innovation: Detailed insights on newly launched products of the next generation drug conjugates market
• Market Development: Comprehensive information about lucrative markets – the report analyses the next generation drug conjugates market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the next generation drug conjugates market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players include Alnylam Pharmaceuticals (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), AstraZeneca (UK), Daiichi Sankyo Company, Limited (Japan), Ionis Pharmaceuticals, Inc. (US), among others in the next generation drug conjugates market

Table of Contents

1 INTRODUCTION 32
1.1 STUDY OBJECTIVES 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED AND REGIONS CONSIDERED 33
1.3.2 INCLUSIONS & EXCLUSIONS 34
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 35
1.4 STAKEHOLDERS 35
2 EXECUTIVE SUMMARY 36
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 36
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 37
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 38
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 39
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 40
3 PREMIUM INSIGHTS 42
3.1 NEXT-GENERATION DRUG CONJUGATES MARKET OVERVIEW 42
3.2 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND & REGION 43
3.3 NEXT-GENERATION DRUG CONJUGATES MARKET: GEOGRAPHIC SNAPSHOT 44
4 MARKET OVERVIEW 45
4.1 INTRODUCTION 45
4.2 MARKET DYNAMICS 45
4.2.1 DRIVERS 46
4.2.1.1 Increasing clinical success and regulatory approvals of antibody-drug conjugates 46
4.2.1.2 Technological advancements in linker chemistry and payload development 47
4.2.2 RESTRAINTS 47
4.2.2.1 High development and manufacturing costs associated with complex biologics 47
4.2.3 OPPORTUNITIES 48
4.2.3.1 Expansion of drug conjugates into non-oncology therapeutic areas 48
4.2.3.2 Increasing developments of novel conjugate platforms 48
4.2.4 CHALLENGES 48
4.2.4.1 Concerns related to biocompatibility, safety, and adverse immune responses 48

4.3 UNMET NEEDS AND WHITE SPACES 49
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 49
4.4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE 50
4.4.2 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE 51
4.4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE 51
4.4.4 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE 52
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52
5 INDUSTRY TRENDS 53
5.1 PORTER’S FIVE FORCES ANALYSIS 53
5.1.1 THREAT OF NEW ENTRANTS 54
5.1.2 THREAT OF SUBSTITUTES 54
5.1.3 BARGAINING POWER OF BUYERS 54
5.1.4 BARGAINING POWER OF SUPPLIERS 54
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 54
5.2 MACROECONOMIC OUTLOOK 55
5.2.1 INTRODUCTION 55
5.2.2 GDP TRENDS AND FORECAST 55
5.2.3 TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET 56
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 58
5.5 PRICING ANALYSIS 60
5.5.1 INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD) 60
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD) 61
5.5.3 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD) 62
5.6 KEY CONFERENCES & EVENTS 63
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 63
5.8 INVESTMENT & FUNDING ACTIVITY 64
5.9 IMPACT OF US TARIFFS—NEXT-GENERATION DRUG CONJUGATES MARKET 65
5.9.1 INTRODUCTION 65
5.9.2 KEY TARIFF RATES 66
5.9.3 PRICE IMPACT ANALYSIS 67
5.9.4 IMPACT ON COUNTRIES/REGIONS 67
5.9.4.1 North America 67
5.9.4.2 Europe 68
5.9.4.3 Asia Pacific 68
5.9.5 IMPACT ON END-USE INDUSTRIES 69
5.9.5.1 Hospitals 69
5.9.5.2 Specialty clinics and cancer centers 69
5.9.5.3 Other specialty care settings 69
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT,
INNOVATIONS, AND FUTURE APPLICATIONS 70
6.1 TECHNOLOGY ANALYSIS 70
6.1.1 KEY TECHNOLOGIES 70
6.1.1.1 New-generation payload chemistries 70
6.1.1.2 Radioligand/theranostic conjugate engineering 70
6.1.2 ADJACENT TECHNOLOGIES 71
6.1.2.1 Protein engineering/antibody engineering 71
6.1.3 COMPLEMENTARY TECHNOLOGIES 71
6.1.3.1 Diagnostic imaging/theranostics workflows 71
6.2 TECHNOLOGY/PRODUCT ROADMAP 71
6.3 FUTURE APPLICATIONS 72
6.4 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET 72
6.4.1 TOP USE CASES AND MARKET POTENTIAL 73
6.4.2 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET 74
6.4.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 74
6.4.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET 75
6.5 PIPELINE ANALYSIS 75
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 77
7.1 REGIONAL REGULATIONS AND COMPLIANCE 77
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 80
7.1.2.1 Reimbursement scenario 81
7.1.3 INDUSTRY STANDARDS 83
7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 84
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 85
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 86
8.1 DECISION-MAKING PROCESS 86
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 86
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
8.2.2 KEY BUYING CRITERIA, BY END USER 87
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 88
8.4 UNMET NEEDS FROM END USERS 89
8.5 MARKET PROFITABILITY 89

9 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT 90
9.1 INTRODUCTION 91
9.2 ENHERTU 91
9.2.1 BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH 91
9.3 PLUVICTO 94
9.3.1 EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH 94
9.4 AMVUTTRA 97
9.4.1 ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING
AND EXPANDED INDICATION REACH 97
9.5 TRODELVY 100
9.5.1 RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS
TO DRIVE MARKET GROWTH 100
9.6 SACITUZUMAB TIRUMOTECAN 103
9.6.1 ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET 103
9.7 PATRITUMAB DERUXTECAN 106
9.7.1 ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES
TO AID GROWTH 106
9.8 225AC-PSMA-617 109
9.8.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH 109
9.9 OTHER COMMERCIALIZED PRODUCTS 112
9.10 OTHER PIPELINE PRODUCTS 115
10 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE 119
10.1 INTRODUCTION 120
10.2 ANTIBODY–SMALL MOLECULE CONJUGATES 120
10.2.1 ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET 120
10.3 PEPTIDE–RADIONUCLIDE CONJUGATES 123
10.3.1 INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH 123
10.4 LIGAND–OLIGONUCLEOTIDE CONJUGATES 126
10.4.1 ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND–OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH 126
10.5 OTHER DRUG CONJUGATES 129
11 NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND 133
11.1 INTRODUCTION 134
11.2 ANTIBODIES 134
11.2.1 ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH 134

11.3 AMINO SUGARS 137
11.3.1 GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION 137
11.4 SMALL MOLECULES 140
11.4.1 EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET 140
11.5 PEPTIDES 143
11.5.1 EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH 143
12 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE 147
12.1 INTRODUCTION 148
12.2 SMALL-MOLECULE PAYLOADS 148
12.2.1 RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH 148
12.3 OLIGONUCLEOTIDE PAYLOADS 151
12.3.1 RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET 151
12.4 RADIONUCLIDE PAYLOADS 154
12.4.1 EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH 154
13 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION 158
13.1 INTRODUCTION 159
13.2 BREAST CANCER 159
13.2.1 RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET 159
13.3 HATTR WITH POLYNEUROPATHY 162
13.3.1 ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH 162
13.4 PROSTATE CANCER 165
13.4.1 EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH 165
13.5 PRIMARY HYPERLIPIDEMIA 168
13.5.1 INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH 168
13.6 OTHER INDICATIONS 171
14 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION 175
14.1 INTRODUCTION 176
14.2 NORTH AMERICA 176
14.2.1 US 180
14.2.1.1 FDA approvals, expanding clinical pipelines, and strategic collaborations drive market 180

14.2.2 CANADA 182
14.2.2.1 Increasing access to innovative NDC therapies drives growth 182
14.3 EUROPE 185
14.3.1 GERMANY 188
14.3.1.1 Access to innovative therapies and strong radioligand infrastructure are driving growth 188
14.3.2 UK 190
14.3.2.1 Rising demand for precision oncology and advanced conjugate technologies drives market expansion 190
14.3.3 FRANCE 193
14.3.3.1 Biopharma presence and global innovation in targeted conjugates support market growth 193
14.3.4 ITALY 195
14.3.4.1 Expanding clinical research to accelerate market growth 195
14.3.5 SPAIN 198
14.3.5.1 Increased focus on research for NDC development to propel market growth 198
14.3.6 REST OF EUROPE 200
14.4 ASIA PACIFIC 203
14.4.1 CHINA 206
14.4.1.1 Strong domestic innovation and expanding oncology demand drive NDC market growth 206
14.4.2 JAPAN 209
14.4.2.1 Growing drug approvals and pharma biotech research initiatives support market growth 209
14.4.3 INDIA 211
14.4.3.1 Expanding biologics capabilities and rising demand for targeted oncology therapies support growth 211
14.4.4 SOUTH KOREA 214
14.4.4.1 Key drug approvals relevant to NDC market to aid growth in South Korea 214
14.4.5 AUSTRALIA 216
14.4.5.1 Strong regulatory framework, clinical innovation, and global partnerships drive market growth 216
14.4.6 REST OF ASIA PACIFIC 219
14.5 LATIN AMERICA 221
14.5.1 BRAZIL 225
14.5.1.1 Expanding clinical trials and rising demand for targeted oncology therapies drive market growth 225
14.5.2 MEXICO 227
14.5.2.1 Gradual increase in pharmaceutical R&D to support market growth 227
14.5.3 REST OF LATIN AMERICA 230

14.6 MIDDLE EAST 232
14.6.1 GCC COUNTRIES 235
14.6.1.1 Integration of genomics, biomarker-driven diagnostics, and personalized treatment to propel market 235
14.6.2 REST OF MIDDLE EAST 238
14.7 AFRICA 240
14.7.1 RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET 240
15 COMPETITIVE LANDSCAPE 243
15.1 OVERVIEW 243
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 243
15.3 REVENUE ANALYSIS, 2021–2025 244
15.4 MARKET SHARE ANALYSIS 245
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 248
15.5.1 STARS 248
15.5.2 EMERGING LEADERS 248
15.5.3 PERVASIVE PLAYERS 248
15.5.4 PARTICIPANTS 248
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 250
15.5.5.1 Company footprint 250
15.5.5.2 Region footprint 251
15.5.5.3 Type footprint 252
15.5.5.4 Indication footprint 253
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 254
15.6.1 PROGRESSIVE COMPANIES 254
15.6.2 RESPONSIVE COMPANIES 254
15.6.3 DYNAMIC COMPANIES 254
15.6.4 STARTING BLOCKS 254
15.6.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 256
15.6.5.1 Detailed list of key startups/SMEs 256
15.7 COMPANY VALUATION AND FINANCIAL METRICS 258
15.8 BRAND COMPARISON 259
15.9 COMPETITIVE SCENARIO 260
15.9.1 PRODUCT APPROVALS 260
15.9.2 DEALS 261
15.9.3 EXPANSIONS 262
16 COMPANY PROFILES 264
16.1 KEY PLAYERS 264
16.1.1 ASTRAZENECA 264
16.1.1.1 Business overview 264
16.1.1.2 Products offered 265
16.1.1.3 Recent developments 266
16.1.1.3.1 Product approvals 266
16.1.1.3.2 Deals 266
16.1.1.3.3 Expansions 267
16.1.1.4 MnM view 267
16.1.1.4.1 Key strengths/Right to win 267
16.1.1.4.2 Strategic choices made 267
16.1.1.4.3 Weaknesses and competitive threats 267
16.1.2 DAIICHI SANKYO COMPANY, LIMITED 268
16.1.2.1 Business overview 268
16.1.2.2 Products offered 269
16.1.2.3 Products in pipeline 269
16.1.2.4 Recent developments 270
16.1.2.4.1 Product approvals 270
16.1.2.4.2 Expansions 270
16.1.2.5 MnM view 270
16.1.2.5.1 Key strengths/Right to win 270
16.1.2.5.2 Strategic choices made 271
16.1.2.5.3 Weaknesses and competitive threats 271
16.1.3 NOVARTIS AG 272
16.1.3.1 Business overview 272
16.1.3.2 Products offered 273
16.1.3.3 Recent developments 274
16.1.3.3.1 Product approvals 274
16.1.3.3.2 Deals 274
16.1.3.3.3 Expansions 275
16.1.3.4 MnM view 276
16.1.3.4.1 Key strengths/Right to win 276
16.1.3.4.2 Strategic choices made 276
16.1.3.4.3 Weaknesses and competitive threats 276
16.1.4 ALNYLAM PHARMACEUTICALS, INC 277
16.1.4.1 Business overview 277
16.1.4.2 Products offered 279
16.1.4.3 Recent developments 279
16.1.4.3.1 Product approvals 279
16.1.4.3.2 Deals 280
16.1.4.3.3 Expansions 280
16.1.4.4 MnM view 281
16.1.4.4.1 Key strengths/Right to win 281
16.1.4.4.2 Strategic choices made 281
16.1.4.4.3 Weaknesses and competitive threats 281

16.1.5 GILEAD SCIENCES, INC. 282
16.1.5.1 Business overview 282
16.1.5.2 Products offered 284
16.1.5.3 Recent developments 284
16.1.5.3.1 Deals 284
16.1.5.3.2 Expansions 285
16.1.5.4 MnM view 285
16.1.5.4.1 Key strengths/Right to win 285
16.1.5.4.2 Strategic choices made 285
16.1.5.4.3 Weaknesses and competitive threats 285
16.1.6 IONIS PHARMACEUTICALS, INC. 286
16.1.6.1 Business overview 286
16.1.6.2 Products offered 287
16.1.6.3 Products in pipeline 287
16.1.6.4 Recent developments 288
16.1.6.4.1 Product approvals 288
16.1.6.4.2 Deals 288
16.1.7 RAKUTEN GROUP, INC. 289
16.1.7.1 Business overview 289
16.1.7.2 Products in pipeline 290
16.1.7.3 Recent developments 291
16.1.7.3.1 Deals 291
16.1.8 NOVO NORDISK 292
16.1.8.1 Business overview 292
16.1.8.2 Products offered 293
16.1.8.3 Recent developments 294
16.1.8.3.1 Product approvals 294
16.1.8.3.2 Deals 294
16.1.9 ADC THERAPEUTICS SA 295
16.1.9.1 Business overview 295
16.1.9.2 Products offered 296
16.1.9.3 Products in pipeline 296
16.1.10 SANOFI 297
16.1.10.1 Business overview 297
16.1.10.2 Products offered 298
16.1.10.3 Products in pipeline 298
16.1.10.4 Recent developments 299
16.1.10.4.1 Deals 299
16.1.11 ARROWHEAD PHARMACEUTICALS 300
16.1.11.1 Business overview 300
16.1.11.2 Products offered 301
16.1.11.3 Recent developments 301
16.1.11.3.1 Product approvals 301
16.1.12 ABBVIE INC. 302
16.1.12.1 Business overview 302
16.1.12.2 Products in pipeline 302
16.1.13 REGENERON PHARMACEUTICALS INC. 303
16.1.13.1 Business overview 303
16.1.13.2 Products in pipeline 303
16.2 OTHER PLAYERS 304
16.2.1 BICYCLE THERAPEUTICS 304
16.2.2 AVIDITY BIOSCIENCES 305
16.2.3 SILENCE THERAPEUTICS 305
16.2.4 MEDILINK THERAPEUTICS 306
16.2.5 SYSTIMMUNE, INC. 306
16.2.6 ACTINIUM PHARMACEUTICALS 307
16.2.7 ALPHAMAB ONCOLOGY 307
16.2.8 FUSION PHARMA 308
16.2.9 ORANO GROUP 308
16.2.10 PEPGEN INC 309
16.2.11 TUBULIS GMBH 309
16.2.12 CLARITY PHARMACEUTICALS 310
17 RESEARCH METHODOLOGY 311
17.1 RESEARCH DATA 311
17.1.1 SECONDARY DATA 312
17.1.2 PRIMARY DATA 313
17.2 MARKET ESTIMATION METHODOLOGY 314
17.2.1 MARKET SIZE ESTIMATION 314
17.2.2 INSIGHTS OF PRIMARY EXPERTS 316
17.2.3 TOP-DOWN APPROACH 317
17.3 MARKET GROWTH RATE PROJECTIONS 318
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 319
17.5 RESEARCH ASSUMPTIONS 320
17.6 RESEARCH LIMITATIONS 321
17.7 RISK ANALYSIS 321
18 APPENDIX 322
18.1 DISCUSSION GUIDE 322
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 326
18.3 CUSTOMIZATION OPTIONS 328
18.4 RELATED REPORTS 329
18.5 AUTHOR DETAILS 330

LIST OF TABLES

TABLE 1 NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS 46
TABLE 2 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE,
2023–2030 (USD BILLION) 50
TABLE 3 PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 51
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION) 51
TABLE 5 BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE,
2022–2029 (USD MILLION) 52
TABLE 6 NEXT-GENERATION DRUG CONJUGATES MARKET:
PORTER’S FIVE FORCES ANALYSIS 54
TABLE 7 NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM 59
TABLE 8 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD) 60
TABLE 9 AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD) 61
TABLE 10 AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD) 62
TABLE 11 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES &
EVENTS, 2026–2027 63
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 66
TABLE 13 CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION
DRUG CONJUGATES MARKET 74
TABLE 14 CLIENT’S READINESS TO ADOPT GENERATIVE AI 75
TABLE 15 KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET
(AS OF MARCH 2026) 76
TABLE 16 EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE 77
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 21 REIMBURSEMENT STATUS AND TYPE, BY COUNTRY 81
TABLE 22 COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS 83
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 87
TABLE 24 KEY BUYING CRITERIA, BY END USER 87
TABLE 25 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 91
TABLE 26 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION) 92
TABLE 27 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 92
TABLE 28 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU,
BY COUNTRY, 2024–2035 (USD MILLION) 93
TABLE 29 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU,
BY COUNTRY, 2024–2035 (USD MILLION) 93
TABLE 30 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION) 94
TABLE 31 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU,
BY REGION, 2024–2035 (USD MILLION) 94
TABLE 32 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION) 95
TABLE 33 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION) 95
TABLE 34 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO,
BY COUNTRY, 2024–2035 (USD MILLION) 96
TABLE 35 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO,
BY COUNTRY, 2024–2035 (USD MILLION) 96
TABLE 36 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024–2035 (USD MILLION) 97
TABLE 37 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO,
BY REGION, 2024–2035 (USD MILLION) 97
TABLE 38 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION) 98
TABLE 39 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 98
TABLE 40 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA,
BY COUNTRY, 2024–2035 (USD MILLION) 99
TABLE 41 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA,
BY COUNTRY, 2024–2035 (USD MILLION) 99
TABLE 42 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION) 100
TABLE 43 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION) 100
TABLE 44 NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION) 101
TABLE 45 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 101
TABLE 46 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY,
BY COUNTRY, 2024–2035 (USD MILLION) 102
TABLE 47 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY,
BY COUNTRY, 2024–2035 (USD MILLION) 102
TABLE 48 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION) 103
TABLE 49 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION) 103
TABLE 50 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION) 104
TABLE 51 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 104
TABLE 52 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 105
TABLE 53 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 105
TABLE 54 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 106
TABLE 55 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION) 106
TABLE 56 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION) 107
TABLE 57 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 107
TABLE 58 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 108
TABLE 59 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 108
TABLE 60 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION) 109
TABLE 61 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION) 109
TABLE 62 NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617,
BY REGION, 2024–2035 (USD MILLION) 110
TABLE 63 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 110
TABLE 64 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 111
TABLE 65 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 111
TABLE 66 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION) 112
TABLE 67 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION) 112
TABLE 68 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 113
TABLE 69 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 113
TABLE 70 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 114
TABLE 71 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 114
TABLE 72 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 115
TABLE 73 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 115
TABLE 74 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 116
TABLE 75 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 116
TABLE 76 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 117
TABLE 77 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 117
TABLE 78 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION) 118
TABLE 79 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION) 118
TABLE 80 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 120
TABLE 81 ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION,
2024–2035 (USD MILLION) 121
TABLE 82 NORTH AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 121
TABLE 83 EUROPE: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 122
TABLE 84 ASIA PACIFIC: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 122
TABLE 85 LATIN AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 123
TABLE 86 MIDDLE EAST: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET,
BY REGION, 2024–2035 (USD MILLION) 123
TABLE 87 PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION,
2024–2035 (USD MILLION) 124
TABLE 88 NORTH AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 124
TABLE 89 EUROPE: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 125
TABLE 90 ASIA PACIFIC: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 125
TABLE 91 LATIN AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 126
TABLE 92 MIDDLE EAST: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 126
TABLE 93 LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION,
2024–2035 (USD MILLION) 127
TABLE 94 NORTH AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 127
TABLE 95 EUROPE: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY,
2024–2035 (USD MILLION) 128
TABLE 96 ASIA PACIFIC: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 128
TABLE 97 LATIN AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 129
TABLE 98 MIDDLE EAST: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 129
TABLE 99 OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION,
2024–2035 (USD MILLION) 130
TABLE 100 NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 130
TABLE 101 EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 131
TABLE 102 ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 131
TABLE 103 LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 132
TABLE 104 MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET,
BY REGION, 2024–2035 (USD MILLION) 132
TABLE 105 NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND,
2024–2035 (USD MILLION) 134
TABLE 106 NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION) 135
TABLE 107 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 135
TABLE 108 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES,
BY COUNTRY, 2024–2035 (USD MILLION) 136
TABLE 109 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 136
TABLE 110 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION) 137
TABLE 111 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION) 137
TABLE 112 NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS,
BY REGION, 2024–2035 (USD MILLION) 138
TABLE 113 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 138
TABLE 114 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 139
TABLE 115 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 139
TABLE 116 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION) 140
TABLE 117 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION) 140
TABLE 118 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES,
BY REGION, 2024–2035 (USD MILLION) 141
TABLE 119 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 141
TABLE 120 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 142
TABLE 121 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 142
TABLE 122 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION) 143
TABLE 123 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION) 143
TABLE 124 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION) 144
TABLE 125 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 144
TABLE 126 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES,
BY COUNTRY, 2024–2035 (USD MILLION) 145
TABLE 127 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES,
BY COUNTRY, 2024–2035 (USD MILLION) 145
TABLE 128 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION) 146
TABLE 129 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES,
BY REGION, 2024–2035 (USD MILLION) 146
TABLE 130 NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD MILLION) 148
TABLE 131 NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 149
TABLE 132 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 149
TABLE 133 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 150
TABLE 134 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 150
TABLE 135 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 151
TABLE 136 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 151
TABLE 137 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 152
TABLE 138 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 152
TABLE 139 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 153
TABLE 140 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 153
TABLE 141 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 154
TABLE 142 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 154
TABLE 143 NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 155
TABLE 144 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 155
TABLE 145 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 156
TABLE 146 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 156
TABLE 147 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION) 157
TABLE 148 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION) 157
TABLE 149 NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 159
TABLE 150 NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER,
BY REGION, 2024–2035 (USD MILLION) 160
TABLE 151 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 160
TABLE 152 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 161
TABLE 153 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 161
TABLE 154 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 162
TABLE 155 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION) 162
TABLE 156 NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION) 163
TABLE 157 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 163
TABLE 158 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 164
TABLE 159 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 164
TABLE 160 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION) 165
TABLE 161 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION) 165
TABLE 162 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER,
BY REGION, 2024–2035 (USD MILLION) 166
TABLE 163 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 166
TABLE 164 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 167
TABLE 165 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 167
TABLE 166 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION) 168
TABLE 167 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION) 168
TABLE 168 NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY
HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION) 169
TABLE 169 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 169
TABLE 170 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 170
TABLE 171 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 170
TABLE 172 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION) 171
TABLE 173 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION) 171
TABLE 174 NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS,
BY REGION, 2024–2035 (USD MILLION) 172
TABLE 175 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 172
TABLE 176 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR
OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 173
TABLE 177 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 173
TABLE 178 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION) 174
TABLE 179 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET
FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION) 174
TABLE 180 NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION,
2024–2035 (USD MILLION) 176
TABLE 181 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 177
TABLE 182 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 178
TABLE 183 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 178
TABLE 184 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 179
TABLE 185 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 179
TABLE 186 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 179
TABLE 187 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 180
TABLE 188 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 181
TABLE 189 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND,
2024–2035 (USD MILLION) 181
TABLE 190 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD MILLION) 182
TABLE 191 US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 182
TABLE 192 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 183
TABLE 193 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 183
TABLE 194 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 184
TABLE 195 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 184
TABLE 196 CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 184
TABLE 197 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY COUNTRY, 2024–2035 (USD MILLION) 185
TABLE 198 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 186
TABLE 199 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 186
TABLE 200 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 187
TABLE 201 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 187
TABLE 202 EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 187
TABLE 203 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 188
TABLE 204 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 189
TABLE 205 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 189
TABLE 206 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 190
TABLE 207 GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 190
TABLE 208 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 191
TABLE 209 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 191
TABLE 210 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND,
2024–2035 (USD MILLION) 192
TABLE 211 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD MILLION) 192
TABLE 212 UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 192
TABLE 213 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 193
TABLE 214 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 194
TABLE 215 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 194
TABLE 216 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 195
TABLE 217 FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 195
TABLE 218 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 196
TABLE 219 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 196
TABLE 220 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 197
TABLE 221 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD MILLION) 197
TABLE 222 ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 197
TABLE 223 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 198
TABLE 224 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 199
TABLE 225 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 199
TABLE 226 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 200
TABLE 227 SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 200
TABLE 228 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 201
TABLE 229 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 201
TABLE 230 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 202
TABLE 231 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 202
TABLE 232 REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 202
TABLE 233 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 204
TABLE 234 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 204
TABLE 235 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 205
TABLE 236 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 205
TABLE 237 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 206
TABLE 238 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 206
TABLE 239 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 207
TABLE 240 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 207
TABLE 241 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 208
TABLE 242 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 208
TABLE 243 CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 208
TABLE 244 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 209
TABLE 245 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 210
TABLE 246 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 210
TABLE 247 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 211
TABLE 248 JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 211
TABLE 249 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 212
TABLE 250 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 212
TABLE 251 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 213
TABLE 252 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE,
2024–2035 (USD MILLION) 213
TABLE 253 INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 213
TABLE 254 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 214
TABLE 255 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 215
TABLE 256 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 215
TABLE 257 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 216
TABLE 258 SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 216
TABLE 259 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 217
TABLE 260 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 217
TABLE 261 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 218
TABLE 262 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 218
TABLE 263 AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 218
TABLE 264 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 219
TABLE 265 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 220
TABLE 266 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 220
TABLE 267 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 221
TABLE 268 REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 221
TABLE 269 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION) 222
TABLE 270 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 222
TABLE 271 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 223
TABLE 272 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 223
TABLE 273 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 224
TABLE 274 LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 224
TABLE 275 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 225
TABLE 276 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 226
TABLE 277 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 226
TABLE 278 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 227
TABLE 279 BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 227
TABLE 280 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 228
TABLE 281 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 228
TABLE 282 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 229
TABLE 283 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 229
TABLE 284 MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 229
TABLE 285 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 230
TABLE 286 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 231
TABLE 287 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 231
TABLE 288 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 232
TABLE 289 REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 232
TABLE 290 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION) 233
TABLE 291 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 233
TABLE 292 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 234
TABLE 293 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 234
TABLE 294 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 235
TABLE 295 MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION) 235
TABLE 296 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION) 236
TABLE 297 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION) 236
TABLE 298 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 237
TABLE 299 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 237
TABLE 300 GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 237
TABLE 301 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PRODUCT, 2024–2035 (USD MILLION) 238
TABLE 302 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TYPE, 2024–2035 (USD MILLION) 239
TABLE 303 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY TARGET LIGAND, 2024–2035 (USD MILLION) 239
TABLE 304 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 239
TABLE 305 REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET,
BY INDICATION, 2024–2035 (USD MILLION) 240
TABLE 306 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT,
2024–2035 (USD MILLION) 241
TABLE 307 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE,
2024–2035 (USD MILLION) 241
TABLE 308 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION) 242
TABLE 309 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION) 242
TABLE 310 AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION,
2024–2035 (USD MILLION) 242
TABLE 311 STRATEGIES ADOPTED BY KEY PLAYERS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2023−2026 243
TABLE 312 NEXT-GENERATION DRUG CONJUGATES MARKET: DEGREE OF COMPETITION 246
TABLE 313 NEXT-GENERATION DRUG CONJUGATES MARKET: REGION FOOTPRINT 251
TABLE 314 NEXT-GENERATION DRUG CONJUGATES MARKET: TYPE FOOTPRINT 252
TABLE 315 NEXT-GENERATION DRUG CONJUGATES MARKET: INDICATION FOOTPRINT 253
TABLE 316 NEXT-GENERATION DRUG CONJUGATES MARKET: KEY STARTUPS/SMES 256
TABLE 317 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 257
TABLE 318 NEXT-GENERATION DRUG CONJUGATES MARKET: PRODUCT APPROVALS,
JANUARY 2023 TO MARCH 2026 260
TABLE 319 NEXT-GENERATION DRUG CONJUGATES MARKET: DEALS,
JANUARY 2023 TO MARCH 2026 261
TABLE 320 NEXT-GENERATION DRUG CONJUGATES MARKET: EXPANSIONS,
JANUARY 2023 TO MARCH 2026 262
TABLE 321 ASTRAZENECA: COMPANY OVERVIEW 264
TABLE 322 ASTRAZENECA: PRODUCTS OFFERED 265
TABLE 323 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023– MARCH 2026 266
TABLE 324 ASTRAZENECA: DEALS, JANUARY 2023–MARCH 2026 266
TABLE 325 ASTRAZENECA: EXPANSIONS, JANUARY 2023–MARCH 2026 267
TABLE 326 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 268
TABLE 327 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 269
TABLE 328 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS IN PIPELINE 269
TABLE 329 DAIICHI SANKYO COMPANY, LIMITED: PRODUCT APPROVALS,
JANUARY 2023–MARCH 2026 270
TABLE 330 DAIICHI SANKYO COMPANY, LIMITED: EXPANSIONS, JANUARY 2023–MARCH 2026 270
TABLE 331 NOVARTIS AG: COMPANY OVERVIEW 272
TABLE 332 NOVARTIS AG: PRODUCTS OFFERED 273
TABLE 333 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 274
TABLE 334 NOVARTIS AG: DEALS, JANUARY 2023–MARCH 2026 274
TABLE 335 NOVARTIS AG: EXPANSIONS, JANUARY 2023–MARCH 2026 275
TABLE 336 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 277
TABLE 337 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 279
TABLE 338 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS,
JANUARY 2023–MARCH 2026 279
TABLE 339 ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026 280
TABLE 340 ALNYLAM PHARMACEUTICALS INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 280
TABLE 341 GILEAD SCIENCES, INC.: COMPANY OVERVIEW 282
TABLE 342 GILEAD SCIENCES, INC.: PRODUCTS OFFERED 284
TABLE 343 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023–MARCH 2026 284
TABLE 344 GILEAD SCIENCES, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026 285
TABLE 345 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 286
TABLE 346 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 287
TABLE 347 IONIS PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE 287
TABLE 348 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS,
JANUARY 2023–MARCH 2026 288
TABLE 349 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026 288
TABLE 350 RAKUTEN GROUP, INC.: COMPANY OVERVIEW 289
TABLE 351 RAKUTEN GROUP, INC.: PRODUCTS IN PIPELINE 290
TABLE 352 RAKUTEN GROUP, INC.: DEALS, JANUARY 2023–MARCH 2026 291
TABLE 353 NOVO NORDISK: COMPANY OVERVIEW 292
TABLE 354 NOVO NORDISK: PRODUCTS OFFERED 293
TABLE 355 NOVO NORDISK: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026 294
TABLE 356 NOVO NORDISK: DEALS, JANUARY 2023–MARCH 2026 294
TABLE 357 ADC THERAPEUTICS SA: COMPANY OVERVIEW 295
TABLE 358 ADC THERAPEUTICS SA: PRODUCTS OFFERED 296
TABLE 359 ADC THERAPEUTICS SA: PRODUCTS IN PIPELINE 296
TABLE 360 SANOFI: COMPANY OVERVIEW 297
TABLE 361 SANOFI: PRODUCTS OFFERED 298
TABLE 362 SANOFI: PRODUCTS IN PIPELINE 298
TABLE 363 SANOFI: DEALS, JANUARY 2023–MARCH 2026 299
TABLE 364 ARROWHEAD PHARMACEUTICALS: COMPANY OVERVIEW 300
TABLE 365 ARROWHEAD PHARMACEUTICALS: PIPELINE PRODUCTS 301
TABLE 366 ARROWHEAD PHARMACEUTICALS: PRODUCT APPROVALS,
JANUARY 2023–MARCH 2026 301
TABLE 367 ABBVIE INC.: COMPANY OVERVIEW 302
TABLE 368 ABBVIE INC.: PRODUCTS IN PIPELINE 302
TABLE 369 REGENERON PHARMACEUTICALS: COMPANY OVERVIEW 303
TABLE 370 REGENERON PHARMACEUTICALS INC.: PRODUCTS IN PIPELINE 303
TABLE 371 BICYCLE THERAPEUTICS: COMPANY OVERVIEW 304
TABLE 372 AVIDITY BIOSCIENCES: COMPANY OVERVIEW 305
TABLE 373 SILENCE THERAPEUTICS: COMPANY OVERVIEW 305
TABLE 374 MEDILINK THERAPEUTICS: COMPANY OVERVIEW 306
TABLE 375 SYSTIMMUNE, INC.: COMPANY OVERVIEW 306
TABLE 376 ACTINIUM PHARMACEUTICALS: COMPANY OVERVIEW 307
TABLE 377 ALPHAMAB ONCOLOGY: COMPANY OVERVIEW 307
TABLE 378 FUSION PHARMA: COMPANY OVERVIEW 308
TABLE 379 ORANO GROUP: COMPANY OVERVIEW 308
TABLE 380 PEPGEN INC.: COMPANY OVERVIEW 309
TABLE 381 TUBULIS GMBH: COMPANY OVERVIEW 309
TABLE 382 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW 310
TABLE 383 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 319

LIST OF FIGURES

FIGURE 1 MARKET SCENARIO 36
FIGURE 2 GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024–2035 37
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023–2026 37
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION
DRUG CONJUGATES MARKET 38
FIGURE 5 HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026–2035 39
FIGURE 6 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 40
FIGURE 7 TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND
PAYLOAD DEVELOPMENT TO DRIVE GROWTH 42
FIGURE 8 ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR
LARGEST MARKET SHARE IN 2025 43
FIGURE 9 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 44
FIGURE 10 NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
FIGURE 11 NEXT-GENERATION DRUG CONJUGATES MARKET:
PORTER’S FIVE FORCES ANALYSIS 53
FIGURE 12 NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS 57
FIGURE 13 NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS 59
FIGURE 14 INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD) 61
FIGURE 15 INDICATIVE SELLING PRICE, BY REGION, 2025 (USD) 62
FIGURE 16 NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64
FIGURE 17 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 64
FIGURE 18 IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET 73
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE 86
FIGURE 20 KEY BUYING CRITERIA, BY END USER 87
FIGURE 21 NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT 177
FIGURE 22 ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT 203
FIGURE 23 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION) 245
FIGURE 24 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 246
FIGURE 25 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 249
FIGURE 26 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT 250
FIGURE 27 NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY
EVALUATION MATRIX (STARTUPS/SMES), 2025 255
FIGURE 28 EV/EBITDA OF KEY VENDORS 258
FIGURE 29 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 258
FIGURE 30 NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS 259
FIGURE 31 ASTRAZENECA: COMPANY SNAPSHOT (2025) 265
FIGURE 32 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024) 268
FIGURE 33 NOVARTIS AG: COMPANY SNAPSHOT (2025) 273
FIGURE 34 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025) 278
FIGURE 35 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025) 283
FIGURE 36 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 286
FIGURE 37 RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025) 290
FIGURE 38 NOVO NORDISK: COMPANY SNAPSHOT (2025) 293
FIGURE 39 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025) 295
FIGURE 40 SANOFI: COMPANY SNAPSHOT (2025) 298
FIGURE 41 ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025) 300
FIGURE 42 RESEARCH DESIGN 311
FIGURE 43 NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES 313
FIGURE 44 NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2025 314
FIGURE 45 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2025 315
FIGURE 46 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025) 315
FIGURE 47 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 316
FIGURE 48 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 317
FIGURE 49 NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS 318
FIGURE 50 DATA TRIANGULATION METHODOLOGY 320

---

---